Friday 6 November 2026 Export BDSX’s income statement to Excel — free account

Biodesix, Inc.

BDSX Healthcare Diagnostics & Research

Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024.

Revenue: +10.4%
EPS: +35.3%
Free cash flow: +12.8%
Total debt: +0.05%

Quarter to September 2026, against a year earlier

10.43 9.41 −47.43%

Follow BDSX

Alert me

Market cap: $209.3M
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 4/9
Altman Z: −7.46
Beneish M: −3.13
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 3.12

Sold, $m 0.12

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	2	—	—	—	—	—	—	2	—	—	—
Sell	—	5	10	—	—	—	—	—	—	—	—	—

Insider Ownership 56.00%

Capital & Financial Ratios $m

Size

Market Cap 209.33

Revenue ttm 105.21

Net income ttm (27.08)

Free cash flow ttm (19.26)

Net debt Q 18.74

Valuation

P/E 0.00

Forward P/E (8.71)

Price / sales 2.01

Forward P/S Powerpack

Price / FCF 0.00

Price / book 24.38

Financial health

Current ratio Q 2.96

Debt / equity Q 5.43

Interest coverage Q (2.72)

Growth

Revenue growth Q +10.44%

Operating income growth Q +13.32%

EPS, this year +42.80%

EPS, next year A +37.54%

Revenue, next year A +26.33%

EPS, past 5 yrs —

EPS, next 5 yrs A +39.91%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 41.31%

10-year low 10-year high

P/B against its own 10 years 78.26%

10-year low 10-year high

EV/Sales against its own 10 years 49.90%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	26	19	28
Receivables	8	9	9	9
Inventory	—	—	—	—
Other	6	5	4	5
	40	39	33	42

	2023	2024	2025	Q'26
Payables	3	2	3	3
ST’ Debt	0	0	0	—
Other	22	1	1	1
	33	14	17	14

Compound Annual Growth %

	10y	5y	3y
Sales	—	14.20%	32.31%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.86 Actual −0.71

−1.77 −1.41 −1.05 −0.68 −0.32

Q3 FY25 Beat +0.44

Q4 FY25 Beat +0.56

Q1 FY26 Beat +0.45

Q2 FY26 Beat +0.15

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−1.60	−1.16	Beat by 0.44
Q4 FY25	−1.05	−0.49	Beat by 0.56
Q1 FY26	−1.26	−0.81	Beat by 0.45
Q2 FY26	−0.86	−0.71	Beat by 0.15
Q3 FY26	−0.74	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.81)	(0.71)	(0.75)	—	—
’25	(1.52)	(1.60)	(1.16)	(0.49)	(4.67)
’24	(2.80)	(1.60)	(1.40)	(1.20)	(6.60)
’23	(4.80)	(3.40)	(2.80)	(1.98)	(12.80)
’22	(10.00)	(8.00)	(6.80)	(7.00)	(31.00)
’21	(5.20)	(8.20)	(8.20)	(9.80)	(31.60)
’20	(743.68)	(601.16)	(638.60)	(5.00)	(129.60)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	26	27	24	—	—
’25	18	20	22	29	88
’24	15	18	18	20	71
’23	9	12	13	15	49
’22	7	11	11	10	38
’21	29	12	7	7	55
’20	5	4	9	27	46

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(2)	(7)	—	—
’25	(9)	(7)	(9)	1	(23)
’24	(15)	(19)	(11)	(4)	(49)
’23	(8)	1	(4)	(12)	(23)
’22	(13)	(10)	(10)	(12)	(45)
’21	(11)	1	(8)	(10)	(28)
’20	(5)	(4)	(4)	(9)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(2)	(8)	—	—
’25	(9)	(7)	(9)	1	(24)
’24	(16)	(21)	(11)	(5)	(52)
’23	(15)	(6)	(10)	(15)	(46)
’22	(13)	(10)	(11)	(14)	(49)
’21	(12)	1	(9)	(11)	(31)
’20	(5)	(4)	(5)	(9)	(24)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	20	25	46	55	38	49	71	88	105		+23.3%	112	135	156	+20.9%
	Gross margin, %	—	—	78.44	75.26	51.71	44.01	62.96	73.50	78.17	81.11	0.00		+2.7 pt	Powerpack Biodesix, Inc.’s next three years, line by line Analysts expect revenue to grow 20.9% a year to 2028 — slower than the 23.3% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	(26)	(31)	(31)	(43)	(65)	(52)	(43)	(35)	(27)		+4.4%
	EBT margin, %	—	—	(128.06)	(125.15)	(68.81)	(79.18)	(171.27)	(106.23)	(60.19)	(39.85)	(25.74)		+88.2 pt
	Net income	—	0	(26)	(31)	(31)	(43)	(65)	(52)	(43)	(35)	(27)		n/m
Per share, $
Per share, $	Revenue	—	—	0.77	2,029.09	188.33	39.83	18.15	11.96	11.02	11.72	9.87		+47.5%
	Earnings	—	—	(0.99)	(2,539.34)	(129.60)	(31.60)	(31.00)	(12.80)	(6.60)	(4.67)	(2.76)		+24.8%
	Cash flow	—	—	(0.67)	(1,795.54)	(88.33)	(20.63)	(21.36)	(5.57)	(7.52)	(3.08)	(1.70)		+24.5%
	Capex	—	—	0.00	(117.02)	(9.00)	(1.86)	(1.68)	(5.62)	(0.53)	(0.05)	(0.10)		n/m
	Free cash flow	—	—	(0.67)	(1,912.56)	(97.33)	(22.49)	(23.04)	(11.19)	(8.05)	(3.14)	(1.81)		+24.8%
	Book value	—	—	(7.46)	(18,606.53)	170.18	14.42	9.79	1.12	3.23	(0.33)	0.81		(36.0%)
	Shares, m	—	—	27	0	0	1	2	4	6	8	10		(16.4%)
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	0.13	0.13	2.14	2.66	2.26	2.98	2.78	0.58	2.01		1.7
	P/B	—	—	0.00	0.00	2.37	7.34	4.19	31.91	9.48	0.00	24.38		6.9
	EV/Sales	—	—	1.92	1.92	1.39	2.24	1.79	3.16	2.92	0.90	2.19		2.0
	EV/FCF	—	—	(2.50)	(2.50)	(2.68)	(3.97)	(1.41)	(3.38)	(4.00)	(3.37)	(11.96)		(3.0)
Cash, $m
Cash, $m	Operating cash flow	—	—	(18)	(22)	(21)	(28)	(45)	(23)	(49)	(23)	(18)		+4.0%
	Capex	—	—	(1)	(1)	(2)	(3)	(4)	(23)	(3)	0	(1)		(5.9%)
	Free cash flow	—	—	(18)	(23)	(24)	(31)	(49)	(46)	(52)	(24)	(19)		+4.3%
Balance, $m
Balance, $m	Working capital	—	—	5	(10)	54	15	30	6	25	15	28		+15.7%
	Net debt	—	—	17	31	(34)	(23)	(18)	9	10	28	19		+7.7%
	Shareholders’ equity	—	—	(198)	(225)	41	20	21	5	21	(2)	9		(46.6%)
Returns, %
Returns, %	ROA	—	—	(133.99)	(73.08)	(37.75)	(43.78)	(77.45)	(54.32)	(43.73)	(38.18)	(29.65)		+95.8 pt
	ROIC	—	—	0.00	0.00	(210.60)	0.00	(1,229.75)	(190.38)	(69.42)	(67.00)	(44.84)		(67.0) pt
	ROE	—	—	12.37	14.52	34.08	(141.75)	(324.53)	(414.09)	(337.30)	(383.09)	(778.89)		(395.5) pt
People
People	Employees	—	—	—	—	200	218	245	217	273	334	—		+10.8%
	Revenue/emp, $m	—	—	0.00	0.00	0.23	0.25	0.16	0.23	0.26	0.26	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+23.90% (above 0%: growing)	n/m	+56.82% (above 0%: growing)	76.75%	(2.65%)	Compare
MYGN Myriad Genetics, Inc.	$601.6M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
FLGT Fulgent Genetics, Inc.	$513.4M	— (loss-making)	— (loss-making)	+7.54% (above 0%: growing)	n/m	+2,058.74% (above 0%: growing)	35.33%	(24.94%)	Compare
BDSX Biodesix, Inc.	$209.3M	— (loss-making)	— (loss-making)	+10.44% (above 0%: growing)	n/m	+12.78% (above 0%: growing)	0.00%	(25.42%)
XGN Exagen Inc.	$184.1M	— (loss-making)	— (loss-making)	+15.92% (above 0%: growing)	n/m	+211.34% (above 0%: growing)	61.27%	(8.64%)	Compare
BNR Burning Rock Biotech Limited Sponsored ADR	$116.5M	— (loss-making)	11.1×	−4.22% (below 0%: shrinking)	n/m	+46.01% (above 0%: growing)	72.58%	(13.36%)	Compare
MDXHF MedX Health Corp.	$103.2M	— (loss-making)	— (loss-making)	+33.59% (above 0%: growing)	n/m	+41.60% (above 0%: growing)	37.19%	(1,027.95%)	Compare
IMDX Insight Molecular Diagnostics Inc.	$80.5M	— (loss-making)	— (loss-making)	−53.86% (below 0%: shrinking)	n/m	−54.02% (below 0%: shrinking)	65.69%	(4,770.71%)	Compare
QUCY Quantum Cyber N.V	$60.8M	— (loss-making)	— (loss-making)	+11.12% (above 0%: growing)	n/m	+26.73% (above 0%: growing)	62.71%	0.00%	Compare
Median of peers	$150.3M	—	—	+9.33%	—	+44.96%	64.20%	(16.88%)

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 9 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	2.24m	666.31k	18.48
2024	2.08m	1.74m	83.15

Ownership

Directors and executive officers, together 23.20%

Jack Schuler and entities affiliated with Jack Schuler 23.20%

Lawrence T. Kennedy, Jr. and entities affiliated with Lawrence T. Kennedy, Jr. 12.90%

Lawrence T. Kennedy, Jr. 12.90%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Biodesix, Inc. (BDSX) Latest News

6 Nov

Impact 3 · 10:31 AM · The Motley Fool transcript

Biodesix (BDSX) Q3 2026 Earnings Call Transcript

Impact 3 · 12:27 AM · GuruFocus.com

Biodesix Inc (BDSX) (Q3 2026) Earnings Call Highlights: Revenue Growth Offset by Sales Force ...

5 Nov

Impact 3 · 6:14 PM · MarketBeat transcript

What Biodesix (BDSX) Said on Its Q3 Earnings Call

Impact 3 · 4:01 PM · GlobeNewswire

Biodesix Announces Third Quarter 2026 Results and Highlights

29 Oct

Impact 3 · 11:00 AM · Zacks

All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy

Impact 3 · 9:00 AM · Zacks

Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know

22 Oct

Impact 3 · 6:00 AM · GlobeNewswire

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

19 Oct

Impact 4 · 4:01 PM · GlobeNewswire

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

Impact 4 · 6:00 AM · GlobeNewswire

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

14 Oct

Impact 4 · 9:15 PM · Simply Wall St.

Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth

13 Oct

Impact 3 · 6:00 AM · GlobeNewswire

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

28 Sep

Impact 4 · 10:03 AM · Zacks

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Impact 3 · 9:09 PM · Simply Wall St.

Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative

24 Sep

Impact 4 · 6:34 AM · InvestorsHub

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Impact 4 · 6:00 AM · GlobeNewswire

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

18 Sep

Impact 3 · 12:11 PM

Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism

31 Aug

Impact 3 · 9:55 AM

Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

12 Aug

Impact 3 · 5:59 PM · The Motley Fool transcript

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

6 Aug

Impact 4 · 1:08 AM transcript

Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic ...

Impact 3 · 8:30 AM · Moby transcript

Biodesix, Inc. Q2 2026 Earnings Call Summary

5 Aug

Impact 4 · 4:01 PM

Biodesix Announces Second Quarter 2026 Results and Highlights

Impact 3 · 7:04 PM · MarketBeat transcript

Biodesix Q2 Earnings Call Highlights

3 Jul

Impact 3 · 10:13 AM

Can Elevance Recover $115 Million Through Its CMS Lawsuit?

26 Jun

Impact 3 · 3:07 PM

Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path

23 May

Impact 3 · 8:16 AM · Insider Monkey

Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions

11 May

Impact 3 · 9:17 AM · GlobeNewswire

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

7 May

Impact 4 · 9:55 AM · Zacks

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

4 May

Impact 4 · 8:16 PM · Moby

Biodesix, Inc. Q1 2026 Earnings Call Summary

Impact 4 · 6:26 PM · The Motley Fool transcript

Biodesix (BDSX) Q1 2026 Earnings Transcript

Impact 3 · 6:17 PM · MarketBeat

Biodesix Q1 Earnings Call Highlights

Biodesix, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Biodesix, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 9 April 2026

Chief executive’s pay

Ownership

Biodesix, Inc. (BDSX) Latest News

6 Nov

5 Nov

29 Oct

22 Oct

19 Oct

14 Oct

13 Oct

28 Sep

24 Sep

18 Sep

31 Aug

12 Aug

6 Aug

5 Aug

3 Jul

26 Jun

23 May

11 May

7 May

4 May

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Biodesix, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 9 April 2026

Chief executive’s pay

Ownership

Biodesix, Inc. (BDSX) Latest News

6 Nov

5 Nov

29 Oct

22 Oct

19 Oct

14 Oct

13 Oct

28 Sep

24 Sep

18 Sep

31 Aug

12 Aug

6 Aug

5 Aug

3 Jul

26 Jun

23 May

11 May

7 May

4 May

Stockrow Weekly